Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1
Skin Research and Technology · 2024
DOI: 10.1111/srt.70020 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Skin Research and Technology, 2024. Verfasst von Jonathan C L Lau und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Imaging, Three-Dimensional, Skin Neoplasms. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Neurofibromatosis Therapeutic Acceleration Program, NSW Office of Health and Medical Research.
Abstract (Originalsprache)
Background
Cutaneous neurofibromas (cNFs) are a major cause of disfigurement in patients with Neurofibromatosis Type 1 (NF1). However, clinical trials investigating cNF treatments lack standardised outcome measures to objectively evaluate changes in cNF size and appearance. 3D imaging has been proposed as an objective standardised outcome measure however various systems exist with different features that affect useability in clinical settings. The aim of this study was to compare the accuracy, precision, feasibility, reliability and accessibility of three imaging systems. Materials and methods We compared the Vectra‐H1, LifeViz‐Micro and Cherry‐Imaging systems. A total of 58 cNFs from 13 participants with NF1 were selected for imaging and analysis. The primary endpoint was accuracy as measured by comparison of measurements between imaging systems. Secondary endpoints included reliability between two operators, precision as measured with the average coefficient of variation, feasibility as determined by time to capture and analyse an image and accessibility as determined by cost.
Results
There was no significant difference in accuracy between the three devices for length or surface area measurements ( p > 0.05), and reliability and precision were similar. Volume measurements demonstrated the most variability compared to other measurements; LifeViz‐Micro demonstrated the least measurement variability for surface area and image capture and analysis were fastest with LifeViz‐Micro. LifeViz‐Micro was better for imaging smaller number of cNFs (1–3), Vectra‐H1 better for larger areas and Cherry for uneven surfaces.
Conclusions
All systems demonstrated excellent reliability but possess distinct advantages and limitations. Surface area is the most consistent and reliable parameter for measuring cNF size in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine and Health, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
- Department of Clinical Genetics, Royal North Shore Hospital, Sydney, New South Wales, Australia.
- Department of Dermatology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
- Faculty of Medicine and Health, Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
- Department of Neurology, John Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Dermatology, National Referral Center for Neurofibromatoses, Henri-Modor Hospital, Assistance Publique-Hopital Paris (AP-HP), Paris, France.
ORCID-Profile: Yemima D Berman
Förderung
- Neurofibromatosis Therapeutic Acceleration Program
- NSW Office of Health and Medical Research
Zitieren
APA
Lau, J. C. L., Fleming, J., Good, M., Lim, A., Saunderson, R. B., Phan, T. A., Schlub, T., Siow, S. F., Lacson, N., Romo, C., Blakely, J., Bergqvist, C., & Berman, Y. D. (2024). Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1. Skin Research and Technology. https://doi.org/10.1111/srt.70020
Vancouver
Lau JCL, Fleming J, Good M, Lim A, Saunderson RB, Phan TA, et al. Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1. Skin Research and Technology. 2024. doi:10.1111/srt.70020
BibTeX
@article{Lau2024,
author = {Lau, Jonathan C L and Fleming, Jane and Good, Martin and Lim, Adrian and Saunderson, Rebecca B and Phan, Tai A and Schlub, Timothy and Siow, Sue-Faye and Lacson, Nanette and Romo, Carlos and Blakely, Jaishri and Bergqvist, Christina and Berman, Yemima D},
title = {Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1},
journal = {Skin Research and Technology},
year = {2024},
doi = {10.1111/srt.70020}
}
EUVIMED